Replimune jumps 85% after FDA opens up third dose for skin cancer therapy
Replimune Group shares soared 85% to $8.64 Friday after the company said it will resubmit its advanced melanoma drug RP1 to the FDA, which agreed to a priority review. The FDA had rejected the therapy in April, citing lack of a control group. Replimune plans to file again within days and will present new trial data at an oncology meeting May 30. Bristol Myers fell 0.6%, while Iovance dropped 6.5%.